scholarly journals Combination of Epithelial Growth Factor Receptor Blockers and CDK4/6 Inhibitor for Nasopharyngeal Carcinoma Treatment

Cancers ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 2954
Author(s):  
Hsin-Pai Li ◽  
Chen-Yang Huang ◽  
Kar-Wai Lui ◽  
Yin-Kai Chao ◽  
Chun-Nan Yeh ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Growth Factor ◽  
Nasopharyngeal Carcinoma ◽  
Egf Receptor ◽  
Young Patients ◽  
Growth Factor Receptor ◽  
Epithelial Growth Factor ◽  
Egfr Expression ◽  
Candidate Target ◽  
Epithelial Growth

Background: Nasopharyngeal carcinoma (NPC) involves host genetics, environmental and viral factors. In clinical observations, patients of young and old ages were found to have higher recurrence and metastatic rates. Methods: Cytokine array was employed to screen druggable target(s). The candidate target(s) were confirmed through patient-derived xenografts (PDXs) and a new EBV-positive cell line, NPC-B13. Results: Overexpression of epithelial growth factor (EGF) and EGF receptor (EGFR) was detected in young patients than in older patients. The growth of NPC PDX tumors and cell lines was inhibited by EGFR inhibitors (EGFRi) cetuximab and afatinib when used separately or in combination with the cell cycle blocker palbociclib. Western blot analysis of these drug-treated PDXs demonstrated that the blockade of the EGF signaling pathway was associated with a decrease in the p-EGFR level and reduction in PDX tumor size. RNA sequencing results of PDX tumors elucidated that cell cycle-related pathways were suppressed in response to drug treatments. High EGFR expression (IHC score ≥ grade 3) was correlated with poor survival in metastatic patients (p = 0.008). Conclusions: Our results provide encouraging preliminary data related to the combination treatment of EGFRi and palbociclib in patients with NPC.

scholarly journals Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival

2018 ◽  
Vol 45 (3) ◽  
Author(s):  
RODRIGO VIEIRA GOMES ◽  
MICHELE ÂNGELA RODRIGUES ◽  
JOÃO BERNARDO SANCIO ROCHA RODRIGUES ◽  
PAULA TEIXEIRA VIDIGAL ◽  
KARINE ARAÚJO DAMASCENO ◽  
...  
Keyword(s):  
Growth Factor ◽  
Growth Factor Receptor ◽  
Female Gender ◽  
Immunohistochemical Expression ◽  
Epithelial Growth Factor ◽  
Kaplan Meier ◽  
Egfr Expression ◽  
Advanced Stages ◽  
Epidermal Growth ◽  
Epithelial Growth

ABSTRACT Objective: to evaluate the expression of the epithelial growth factor receptor (EGFR) by immunohistochemistry, and to verify its association with prognostic factors and survival of patients operated by cholangiocarcinoma. Methods: we verified the immunohistochemical expression of EGFR in 35 surgical specimens of cholangiocarcinoma (CCA). We obtained survival curves with the Kaplan-Meier method. Results: we found significant EGFR expression in ten (28.6%) of the 35 CCAs, eight with score 3 and two with score 2. Advanced stages (III and IV) presented higher EGFR expression (p=0.07). The clinical characteristics that were most associated with positive EGFR expression were female gender (p=0.06) and absence of comorbidities (p=0.06). Overall survival at 12, 24, 36 and 48 months was 100%, 82.5%, 59% and 44.2%, respectively. The survival of EGFR positive patients at 12, 24, 36 and 48 months was 100%, 75%, 50% and 0%, whereas for negative EGFR patients it was 100%, 87.5%, 65.6% and 65.6%, respectively. Conclusion: EGFR expression occurred in 28.6% of the cases studied and was associated with lower survival.

Prostasin Impairs Epithelial Growth Factor Receptor Activation to Suppress Dengue Virus Propagation

2018 ◽  
Vol 219 (9) ◽  
pp. 1377-1388 ◽  
Author(s):  
Chun-Kuang Lin ◽  
Chin-Kai Tseng ◽  
Yu-Hsuan Wu ◽  
Chun-Yu Lin ◽  
Chung-Hao Huang ◽  
...  
Keyword(s):  
Growth Factor ◽  
Dengue Virus ◽  
Growth Factor Receptor ◽  
Receptor Activation ◽  
Epithelial Growth Factor Receptor ◽  
Virus Propagation ◽  
Epithelial Growth Factor ◽  
Epithelial Growth

scholarly journals Increased Eps15 homology domain 1 and RAB11FIP3 expression regulate breast cancer progression via promoting epithelial growth factor receptor recycling

Tumor Biology ◽  
2017 ◽  
Vol 39 (2) ◽  
pp. 101042831769101 ◽  
Author(s):  
Dandan Tong ◽  
Ya-Nan Liang ◽  
AA Stepanova ◽  
Yu Liu ◽  
Xiaobo Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Epithelial Growth Factor Receptor ◽  
Epithelial Growth Factor ◽  
Epidermal Growth ◽  
Epithelial Growth ◽  
Eps15 Homology Domain

Recent research indicates that the C-terminal Eps15 homology domain 1 is associated with epithelial growth factor receptor–mediated endocytosis recycling in non-small-cell lung cancer. The aim of this study was to determine the clinical significance of Eps15 homology domain 1 gene expression in relation to phosphorylation of epithelial growth factor receptor expression in patients with breast cancer. Primary breast cancer samples from 306 patients were analyzed for Eps15 homology domain 1, RAB11FIP3, and phosphorylation of epithelial growth factor receptor expression via immunohistochemistry. The clinical significance was assessed via a multivariate Cox regression analysis, Kaplan–Meier curves, and the log-rank test. Eps15 homology domain 1 and phosphorylation of epithelial growth factor receptor were upregulated in 60.46% (185/306) and 53.92% (165/306) of tumor tissues, respectively, as assessed by immunohistochemistry. The statistical correlation analysis indicated that Eps15 homology domain 1 overexpression was positively correlated with the increases in phosphorylation of epithelial growth factor receptor ( r = 0.242, p < 0.001) and RAB11FIP3 ( r = 0.165, p = 0.005) expression. The multivariate Cox proportional hazard model analysis demonstrated that the expression of Eps15 homology domain 1 alone is a significant prognostic marker of breast cancer for the overall survival in the total, chemotherapy, and human epidermal growth factor receptor 2 (−) groups. However, the use of combined expression of Eps15 homology domain 1 and phosphorylation of epithelial growth factor receptor markers is more effective for the disease-free survival in the overall population, chemotherapy, and human epidermal growth factor receptor 2 (−) groups. Moreover, the combined markers are also significant prognostic markers of breast cancer in the human epidermal growth factor receptor 2 (+), estrogen receptor (+), and estrogen receptor (−) groups. Eps15 homology domain 1 has a tumor suppressor function, and the combined marker of Eps15 homology domain 1/phosphorylation of epithelial growth factor receptor expression was identified as a better prognostic marker in breast cancer diagnosis. Furthermore, RAB11FIP3 combines with Eps15 homology domain 1 to promote the endocytosis recycling of phosphorylation of epithelial growth factor receptor.

Sign in / Sign up

Export Citation Format

Share Document